AJCN EB Program 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Roos, B.
Right arrow Articles by Packard, C. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Roos, B.
Right arrow Articles by Packard, C. J
Agricola
Right arrow Articles by de Roos, B.
Right arrow Articles by Packard, C. J
American Journal of Clinical Nutrition, Vol. 73, No. 1, 45-52, January 2001
© 2001 American Society for Clinical Nutrition

Original Research Communication

The coffee diterpene cafestol increases plasma triacylglycerol by increasing the production rate of large VLDL apolipoprotein B in healthy normolipidemic subjects1,2,3

Baukje de Roos, Muriel J Caslake, Anton FH Stalenhoef, Dorothy Bedford, Pierre NM Demacker, Martijn B Katan and Chris J Packard

1 From the Division of Human Nutrition and Epidemiology, Wageningen University, Wageningen, Netherlands; the Department of Pathological Biochemistry, Glasgow Royal Infirmary, Glasgow, United Kingdom; and the Division of Internal Medicine, University Hospital Nijmegen, Nijmegen, Netherlands.

Background: Cafestol is a diterpene in unfiltered coffee that raises plasma triacylglycerol in humans.

Objective: We studied whether cafestol increases plasma triacylglycerol by increasing the production rate or by decreasing the fractional catabolic rate of VLDL1 [Svedberg flotation unit (Sf) 60–400] apolipoprotein (apo) B. In addition, we studied the effect of cafestol on the composition of VLDL1 and VLDL2 (Sf 20–60).

Design: Eight healthy normolipidemic men were administered a daily dose of 75 mg cafestol for 2 wk. A bolus injection of 7 mg L-[5,5,5-2H3]leucine/kg body wt was given after a baseline period with no cafestol and again after treatment with cafestol. We derived kinetic constants to describe the metabolism of VLDL1 apo B by using a multicompartmental model.

Results: Cafestol significantly increased plasma triacylglycerol by 31% or 0.32 mmol/L (95% CI: 0.03, 0.61); the increase was due mainly to a nonsignificant rise in VLDL1 triacylglycerol of 57% or 0.23 mmol/L (95% CI: -0.02, 0.48). Cafestol significantly increased the mean rate of VLDL1 apo B production by 80% or 755 mg/d (95% CI: 0.2, 5353), whereas it did not significantly change the mean fractional catabolic rate of VLDL1 apo B (mean increase of 3 pools/d; 95% CI: -4, 10]). Cafestol did not change the composition of VLDL1. A significant increase in the ratio of VLDL2 cholesteryl ester to triacylglycerol indicates that VLDL2 became enriched with cholesteryl esters at the cost of triacylglycerol.

Conclusion: Cafestol increases plasma triacylglycerol by increasing the production rate of VLDL1 apo B, probably via increased assembly of VLDL1 in the liver.

Key Words: Healthy men • cafestol • VLDL1 apolipoprotein B • catabolism • VLDL composition • unfiltered coffee • cafetière coffee • French-press coffee • triacylglycerol • triglyceride






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by The American Society for Nutrition